Document:

<PAGE>

                                                                    Exhibit 10.4

                         WATSON PHARMACEUTICALS, INC.

                            KEY EMPLOYEE AGREEMENT

     This Key Employee Agreement ("Agreement") is entered into as of __________,
2000 (the "Effective Date"), by and between ________________________
("Executive") and Watson Pharmaceuticals, Inc. (the "Company"), a Nevada
corporation.

     Whereas, the Company desires to employ Executive to provide personal
services to the Company, and wishes to provide Executive with certain
compensation and benefits in return for his services; and

     Whereas, Executive wishes to be employed by the Company and provide
personal services to the Company in return for certain compensation and
benefits, including the benefits provided under the Agreement;

     Now, Therefore, in consideration of the mutual promises and covenants
contained herein, it is hereby agreed by and between the parties hereto as
follows:

     1.   Employment by the Company. Subject to terms set forth herein, the
Company agrees to employ Executive in the position of _______________ and
Executive hereby accepts employment effective as of the Effective Date. In this
position, Executive shall perform such duties as are assigned from time to time
by the Chief Executive Officer ("CEO") of the Company, consistent with the
Bylaws of the Company and as may be required by the Company's Board of Directors
(the "Board"). During his employment with the Company, Executive will devote his
best efforts and substantially all of his business time and attention (except
for vacation periods as set forth herein and reasonable periods of illness or
other incapacity permitted by the Company's general employment policies) to the
business of the Company. Executive shall abide by the general employment
policies and procedures of the Company, except that wherever the terms of this
Agreement may differ from or are in conflict with the Company's general
employment policies or procedures, this Agreement shall control.

     2.   Compensation.

          2.1   Salary. For services to be rendered hereunder, Executive shall
receive a base salary as set forth in Section 1 of the Compensation and
Severance Terms Schedule, attached hereto as Exhibit A. Executive will be
considered annually for increases in base salary in accordance with Company
policy and subject to review and approval by the CEO or the Compensation
Committee of the Board, as appropriate.

          2.2   Bonus. Executive shall be eligible to participate in the
Company's bonus plan at the executive level throughout the duration of
Executive's employment with the Company. The Company shall have the sole
discretion to determine whether Executive is entitled to any such bonus and to
determine the amount of the bonus. The amount of Executive's bonus may be
determined in part based on Executive's performance with respect to certain
goals

                                       1.
<PAGE>

established by the Company and attainment by the Company of its planned
financial objectives for the bonus period. Notwithstanding the foregoing, no
bonus is guaranteed to Executive. Any bonus is subject to the approval of the
CEO or the Compensation Committee of the Board, as appropriate. The Company
retains the authority to review, grant, deny or revise any bonus in its sole
discretion. To be eligible to receive a bonus, Executive must remain in
employment with the Company throughout the entire fiscal year. The target level
of such bonus is set forth in Section 2 of Exhibit A attached hereto.

          2.3   Stock Options. In addition to any stock options which the
Company may have already granted to Executive prior to the Effective Date,
subject to approval of the Board or the Compensation Committee of the Board, as
appropriate, Executive will receive the stock option grants (if any) set forth
in Section 3 of Exhibit A, and such additional grants of stock options as may
from time to time be granted, pursuant to the terms and conditions set forth in
the applicable stock option agreement and plan documents, copies of which will
be made available upon Executive's request. For the purposes of this Agreement,
all stock options granted to Executive by the Company prior to the Effective
Date, granted hereunder, or granted in the future shall be referred to
hereinafter as the "Options."

          2.4   Paid Time Off. Executive shall be eligible to accrue paid time
off ("PTO") during the term of this Agreement, in accordance with the Company's
standard policy regarding PTO and in an amount commensurate with other employees
at a level similar to that of the Executive.

          2.5   Standard Company Benefits. Executive shall be entitled to all
rights and benefits for which he is eligible under the terms and conditions of
the standard Company benefits plans (e.g., health and disability insurance,
401(k) retirement plan, etc.) and other benefits and incentives which may be in
effect from time to time and provided by the Company to employees at levels
similar to the Executive.

     3.   Proprietary Information and Inventions.

          Executive agrees to execute and abide by the Employee Proprietary
Information and Inventions Agreement attached hereto as Exhibit C and made a
part hereof by this reference.

     4.   Outside Activities.

          4.1   Activities. Except with the prior written consent of the CEO or
the Board, as appropriate, Executive will not during his employment with the
Company undertake or engage in any other employment, occupation or business
enterprise, other than ones in which Executive is a passive investor. Executive
may engage in civic and not-for-profit activities so long as such activities do
not materially interfere with the performance of his duties hereunder.

          4.2   Investments and Interests. During his employment by the Company,
Executive agrees not to acquire, assume or participate in, directly or
indirectly, any position, investment or interest known by him to be adverse to
or in conflict with the interest of the Company, its business or prospects,
financial or otherwise. By way of clarification, nothing contained in this
Agreement shall prevent Executive from holding, for investment purposes only, no
more than one percent (1%) of the capital stock of any publicly traded company.

                                       2.
<PAGE>

          4.3   Non-Competition. During his employment by the Company, except on
behalf of the Company, Executive will not directly or indirectly, whether as an
officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially
interested in, be employed by or have any business connection with any other
person, corporation, firm, partnership or other entity whatsoever known by him
to compete directly with the Company, anywhere in the world, in any line of
business engaged in (or planned to be engaged in) by the Company.

     5.   Other Agreements.

          Executive represents and warrants that his employment by the Company
will not conflict with and will not be constrained by any prior agreement or
relationship with any third party.  Executive represents and warrants that he
will not disclose to the Company or use on behalf of the Company any
confidential information governed by any agreement with any third party except
in accordance with an agreement between the Company and any such third party.
During Executive's employment by the Company, Executive may use, in the
performance of his duties, all information generally known and used by persons
with training and experience comparable to his own and all information which is
common knowledge in the industry or otherwise legally in the public domain.

     6.   Termination Of Employment.

          6.1   At-Will Employment. Executive's relationship with the Company is
at-will. The Company shall have the right to terminate Executive's employment
with the Company at any time with or without Cause and with or without notice.

          6.2   Termination by Company for Cause. If the Company terminates
Executive's employment at any time for Cause, Executive's salary shall cease on
the date of termination; and Executive will not be entitled to severance pay,
pay in lieu of notice or any other such compensation.

                (a)   Definition of "Cause." For purposes of this Agreement,
"Cause" shall mean (i) Executive's conviction of any felony; or, (ii)
Executive's gross misconduct, material violation of Company policy, or material
breach of Executive's duties to the Company, which Executive fails to correct
within thirty (30) days after Executive is given written notice by the CEO or
the Board, as appropriate.

          6.3   Termination by Company Without Cause.  If the Company terminates
Executive's employment at any time without Cause, Executive shall be entitled to
severance benefits as set forth in Section 4.1 of the Compensation and Severance
Terms Schedule, attached hereto as Exhibit A.

          6.4   Executive's Voluntary Resignation. Executive may terminate his
employment with the Company at any time, with or without Good Reason, and with
or without notice. In the event Executive voluntarily terminates his employment
other than for Good Reason, he will not be entitled to severance pay, pay in
lieu of notice or any other such compensation.

                                       3.
<PAGE>

          6.5   Executive's Resignation for Good Reason. Executive may resign
his employment for Good Reason so long as Executive tenders his resignation to
the Company within sixty (60) days after the occurrence of the event which forms
the basis for his termination for Good Reason. If Executive terminates his
employment for Good Reason, Executive shall be eligible for severance benefits
as set forth in Section 4.2 of Exhibit A, attached hereto.

                (a)   Definition of "Good Reason." For purposes of this
Agreement, "Good Reason" shall mean any one of the following events which occurs
on or after the Effective Date: (i) any reduction of the Executive's then
existing annual base salary, except to the extent the annual base salary of all
other executive officers of the Company is similarly reduced (provided such
reduction does not exceed fifteen percent (15%) of Executive's then existing
annual base salary); (ii) any material reduction in the package of benefits and
incentives, taken as a whole, provided to the Executive (except that employee
contributions may be raised to the extent of any cost increases imposed by third
parties) or any action by the Company which would materially and adversely
affect the Executive's participation or reduce the Executive's benefits under
any such plans, except to the extent that such benefits and incentives of all
other executive officers of the Company are similarly reduced; (iii) any
diminution of the Executive's duties, responsibilities, authority, reporting
structure, titles or offices, excluding for this purpose an isolated,
insubstantial or inadvertent action not taken in bad faith which is remedied by
the Company immediately after notice thereof is given by the Executive; (iv)
request that the Executive relocate to a work site that would increase the
Executive's one-way commute distance by more than thirty-five (35) miles from
his then principal residence, unless the Executive accepts such relocation
opportunity; (v) any material breach by the Company of its obligations under
this Agreement; or (vi) any failure by the Company to obtain the assumption of
this Agreement by any successor or assign of the Company.

          6.6   Termination for Death or Disability. Executive's employment with
the Company will be terminated in the event of Executive's death, or any
illness, disability or other incapacity in such a manner that Executive is
physically rendered unable regularly to perform his duties hereunder for a
period in excess of one hundred eighty (180) consecutive days or more than one
hundred eighty (180) days in any consecutive twelve (12) month period. The
determination regarding whether Executive is physically unable regularly to
perform his duties shall be made by the Board. Executive's inability to be
physically present on the Company's premises shall not constitute a presumption
that Executive is unable to perform such duties. In the event that Executive's
employment with the Company is terminated for death or disability as described
in this Section 6.6, Executive or Executive's heirs, successors, and assigns
shall not receive any compensation or benefits other than payment of accrued
salary and PTO and such other benefits as expressly required in such event by
applicable law or the terms of applicable benefit plans.

          6.7   Cessation. If Executive violates any provision of Section 8 of
this Agreement or the Employee Proprietary Information and Inventions Agreement
and Executive fails to correct such violation within ten (10) days after
Executive is given written notice by the CEO or the Board, as appropriate, then
any severance payments or other benefits being provided to Executive will cease
immediately, and Executive will not be entitled to any further compensation from
the Company.

                                       4.
<PAGE>

     7.   Change of Control.

          7.1   Definition. For purposes of this Agreement, Change of Control
means the occurrence of any of the following:

                (a)   a sale of assets representing fifty percent (50%) or more
of the net book value and of the fair market value of the Company's consolidated
assets (in a single transaction or in a series of related transactions);

                (b)   a liquidation or dissolution of the Company;

                (c)   a merger or consolidation involving the Company or any
subsidiary of the Company after the completion of which: (i) in the case of a
merger (other than a triangular merger) or a consolidation involving the
Company, the shareholders of the Company immediately prior to the completion of
such merger or consolidation beneficially own (within the meaning of Rule 13d-3
promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or comparable successor rules), directly or indirectly, outstanding
voting securities representing less than sixty percent (60%) of the combined
voting power of the surviving entity in such merger or consolidation, and (ii)
in the case of a triangular merger involving the Company or a subsidiary of the
Company, the shareholders of the Company immediately prior to the completion of
such merger beneficially own (within the meaning of Rule 13d-3 promulgated under
the Exchange Act, or comparable successor rules), directly or indirectly,
outstanding voting securities representing less than sixty percent (60%) of the
combined voting power of the surviving entity in such merger and less than sixty
percent (60%) of the combined voting power of the parent of the surviving entity
in such merger;

                (d)   an acquisition by any person, entity or "group" (within
the meaning of Section 13(d) or 14(d) of the Exchange Act or any comparable
successor provisions), other than any employee benefit plan, or related trust,
sponsored or maintained by the Company or an affiliate of the Company and other
than in a merger or consolidation of the type referred to in clause "(c)" of
this sentence, of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act, or comparable successor rules) of
outstanding voting securities of the Company representing more than thirty
percent (30%) of the combined voting power of the Company (in a single
transaction or series of related transactions); or

                (e)   in the event that the individuals who, as of the Effective
Date, are members of the Board (the "Incumbent Board"), cease for any reason to
constitute at least fifty percent (50%) of the Board. (If the election, or
nomination for election by the Company's shareholders, of any new member of the
Board is approved by a vote of at least fifty percent (50%) of the Incumbent
Board, such new member of the Board shall be considered as a member of the
Incumbent Board.)

          7.2   Termination After a Change of Control. In the event Executive's
employment with the Company is terminated without Cause, or Executive resigns
for Good Reason, within ninety (90) days prior to or twenty-four (24) months
following a Change of Control (a "Change of Control Termination"), then
Executive shall be eligible for severance benefits as set forth in Section 4.3
of Exhibit A, attached hereto.

                                       5.
<PAGE>

          7.3   Parachute Payments. In the event that it shall be determined
under this Section 7.3 that any payment or benefit to Executive or for the
benefit of Executive or on Executive's behalf (whether paid or payable or
distributed or distributable) pursuant to the terms of this Agreement or any
other agreement, arrangement or plan with the Company or any Affiliate (as
defined below) (including, without limitation, the severance benefits as set
forth in Section 4.3 of Exhibit A, attached hereto) (individually, a "Payment"
and collectively, the "Payments") would be subject to the excise tax imposed by
Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), or
any successor provision thereto (the "Excise Tax"), then Executive shall be
entitled to receive from the Company one or more additional payments
(individually, a "Gross-Up Payment" and collectively, the "Gross-Up Payments")
in an aggregate amount such that the net amount of the Payments and the Gross-Up
Payments retained by Executive after the payment of all Excise Taxes (and any
interest and penalties imposed with respect to such Excise Taxes) on the
Payments and all federal, state and local income tax, employment taxes and
Excise Taxes (including any interest and penalties imposed with respect to such
taxes and Excise Taxes) on the Gross-Up Payments provided for in this Section
7.3, and taking into account any lost or reduced tax deductions on account of
the Gross-Up Payments, shall be equal to the Payments.  For purposes of this
Section 7.3, an "Affiliate" shall mean any successor to all or substantially all
of the business and/or assets of the Company, any person acquiring ownership or
effective control of the Company or ownership of a substantial portion of the
assets of the Company's assets, or any other person whose relationship to the
Company, such successor or such person acquiring ownership or control is such as
to require attribution between the parties under Section 318(a) of the Code.

                (a)   All determinations required to be made under this Section
7.3, including whether and when any Gross-Up Payment is required and the amount
of such Gross-Up Payment, and the assumptions to be utilized in arriving at such
determinations, shall be made by the Accountants (as defined below), which shall
provide Executive and the Company with detailed supporting calculations with
respect to such Gross-Up Payment within thirty (30) days of the receipt of
notice from Executive or the Company that Executive has received or will receive
a Payment. For the purposes of this Section 7.3, the "Accountants" shall mean
the Company's independent certified public accounting firm serving immediately
prior to the Change of Control (or other change in ownership or effective
control, or change in ownership of a substantial portion of the assets, of a
corporation, as defined in Section 280G of the Code) with respect to which such
determination is being made. In the event that the Accountants are also serving
as the accountants, auditors or consultants for the individual, entity or group
effecting the Change of Control (or other change in ownership or effective
control, or change in ownership of a substantial portion of the assets, of a
corporation, as defined in Section 280G of the Code), the Company shall appoint
another nationally recognized independent certified public accounting firm,
reasonably acceptable to Executive, to make the determinations required
hereunder (which accounting firm shall then be referred to as the "Accountants"
hereunder). All fees and expenses of the Accountants shall be borne solely by
the Company.

                (b)   For the purposes of determining whether any of the
Payments will be subject to the Excise Tax and the amount of such Excise Tax,
such Payments will be treated as "parachute payments" within the meaning of
section 280G of the Code, and all "parachute payments" in excess of the "base
amount" (as defined under Section 280G(b)(3) of the Code) of Executive shall be
treated as subject to the Excise Tax, unless and except to the extent that, in
the opinion of the Accountants, such Payments (in whole or in part) either do
not constitute "parachute payments" or represent reasonable compensation for
services actually rendered

                                       6.
<PAGE>

(within the meaning of section 280G(b)(4) of the Code) in excess of the "base
amount," or such "parachute payments" are otherwise not subject to such Excise
Tax.

                (c)   For purposes of determining the amount of the Gross-Up
Payment, Executive shall be deemed to pay federal income taxes at the highest
applicable marginal rate of federal income taxation for the calendar year in
which the Gross-Up Payment is to be made and to pay any applicable state and
local income taxes at the highest applicable marginal rate of taxation for the
calendar year in which the Gross-Up Payment is to be made, net of the maximum
reduction in federal income taxes which could be obtained from the deduction of
such state or local taxes if paid in such year (determined without regard to
limitations on deductions based upon the amount of Executive's adjusted gross
income); and to have otherwise allowable deductions for federal, state and local
income tax purposes at least equal to those disallowed because of the inclusion
of the Gross-Up Payment in Executive's adjusted gross income.

                (d)   Any determination by the Accountants shall be binding upon
the Company and Executive. As a result of uncertainty in the application of
Section 4999 of the Code at the time of the initial determination by the
Accountants hereunder, it is possible that the Gross-Up Payment made will have
been an amount less than the Company should have paid pursuant to this Section
7.3 (the "Underpayment"). In the event that the Company exhausts its remedies
pursuant to Section 7.3(f) and Executive is required to make a payment of any
Excise Tax, the Underpayment shall be promptly paid by the Company to or for
Executive's benefit.

                (e)   Executive shall notify the Company in writing of any claim
by the Internal Revenue Service or other taxing authority that, if successful,
would require the payment by the Company of a Gross-Up Payment. Such
notification shall be given as soon as practicable after Executive is informed
in writing of such claim and shall apprise the Company of the nature of such
claim and the date on which such claim is requested to be paid. Executive shall
not pay such claim prior to the expiration of the 30-day period following the
date on which Executive gives such notice to the Company (or such shorter period
ending on the date that any payment of taxes, interest and/or penalties with
respect to such claim is due). If the Company notifies Executive in writing
prior to the expiration of such period that the Company desires to contest such
claim, Executive shall: (i) give the Company any information reasonably
requested by the Company relating to such claim; (ii) take such action in
connection with contesting such claim as the Company shall reasonably request in
writing from time to time, including, without limitation, engaging legal
representation with respect to such claim by an attorney selected by the Company
and reasonably acceptable to Executive; (iii) cooperate with the Company in good
faith in order to effectively contest such claim; and (iv) permit the Company to
participate in any proceedings relating to such claims; provided, however, that
the Company shall bear and pay directly all costs and expenses, including
attorneys' fees (including additional interest and penalties) incurred in
connection with such contest and shall indemnify Executive for and hold
Executive harmless from, on an after-tax basis, any Excise Tax or income,
employment or other taxes (including interest and penalties with respect
thereto) imposed as a result of such representation and payment of all related
costs and expenses.

                (f)   Without limiting the foregoing provisions of this Section
7.3, the Company shall control all proceedings taken in connection with such
contest and, at the

                                       7.
<PAGE>

Company's sole option, may pursue or forgo any and all administrative appeals,
proceedings, hearings and conferences with the Internal Revenue Service or other
taxing authority in respect of such claim and may, at the Company's sole option,
either direct Executive to pay the amount claimed and sue for a refund or
contest the claim in any permissible manner, and Executive agrees to prosecute
such contest to a determination before any administrative tribunal, in a court
of initial jurisdiction and in one or more appellate courts, as the Company
shall determine; provided, however, that if the Company directs Executive to pay
such claim and sue for a refund, the Company shall advance the amount of such
payment to Executive, on an interest-free basis, and shall indemnify Executive
for and hold Executive harmless from, on an after-tax basis, any Excise Tax or
income, employment or other taxes (including interest or penalties with respect
thereto) imposed with respect to such advance or with respect to any imputed
income with respect to such advance (including as a result of any forgiveness by
the Company of such advance); provided, further, that any extension of the
statute of limitations relating to the payment of taxes, interest and penalties
for the taxable year of Executive with respect to which such contested amount is
claimed to be due shall be limited solely to such contested amount. Furthermore,
the Company's control of the contest shall be limited to issues with respect to
which a Gross-Up Payment would be payable hereunder and Executive shall be
entitled to settle or contest, as the case may be, any other issue raised by the
Internal Revenue Service or any other taxing authority.

                (g)   The Gross-Up Payments provided for in this Section 7.3
shall be paid to Executive not later than the date upon which the severance
benefits payable to Executive under Section 4.3 of Exhibit A, attached hereto,
are due; provided, however, that if the amounts of such Gross-Up Payments cannot
be finally determined by the Accountants on or before such day, the Company
shall pay to Executive on such day an estimate, as determined in good faith by
the Company, of the minimum amount of such Gross-Up Payments and shall pay the
remainder of such Gross-Up Payments (together with interest at the rate provided
in Section 1274(b)(2)(B) of the Code) not later than 30 days after the amount
thereof can be determined by the Accountants. In the event that the amount of
the estimated payments exceeds the amount subsequently determined by the
Accountants to have been due to the Executive, such excess shall constitute a
loan by the Company to Executive, payable not later than 30 days after such
determination and demand by the Company (together with interest at the rate
provided in Section 1274(b)(2)(B) of the Code).

     8.   Nonsolicitation.  While employed by the Company, and for one (1) year
following the termination of Executive's employment with the Company, Executive
agrees not to solicit, attempt to solicit, induce, or otherwise cause any
employee or independent contractor of the Company to terminate his or her
employment or contractual relationship in order to become an employee or
independent contractor to or for Executive or any other person or entity.

     9.   Release.  In exchange for the severance compensation and benefits
provided under this Agreement to which Executive would not otherwise be
entitled, Executive shall enter into and execute a release substantially in the
form attached hereto as Exhibit B (the "Release") upon Executive's termination
of employment. Unless the Release is executed by Executive and delivered to the
Company within twenty-one (21) days (forty-five (45) days in the event of a
group termination) after the termination of Executive's employment with the
Company, Executive shall not receive any severance benefits provided under this
Agreement, acceleration,

                                       8.
<PAGE>

if any, of Executive's Options as provided in this Agreement shall not apply and
Executive's Options in such event may be exercised following the date of
Executive's termination only to the extent provided under their original terms
in accordance with the applicable stock option plan and option agreements.

     10.  General Provisions.

          10.1  Notices. Any notices provided hereunder must be in writing and
shall be deemed effective upon personal delivery (including, personal delivery
by facsimile transmission) or the third day after mailing by first class mail,
to the Company at its primary office location and to Executive at his address as
listed on the Company payroll (which address may be changed by written notice).

          10.2  Severability. Whenever possible, each provision of this
Agreement will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be invalid or
unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity or unenforceability will not affect any other
provision or any other jurisdiction, and such invalid or unenforceable provision
shall be reformed, construed and enforced in such jurisdiction so as to render
it valid and enforceable consistent with the intent of the parties insofar as
possible.

          10.3  Waiver. If either party should waive any breach of any
provisions of this Agreement, he or it shall not thereby be deemed to have
waived any preceding or succeeding breach of the same or any other provision of
this Agreement.

          10.4  Entire Agreement. This Agreement, together with the Employee
Proprietary Information and Inventions Agreement, constitute the final,
complete, and exclusive embodiment of the entire agreement between Executive and
the Company regarding the subject matter hereof and supersede any prior
agreement, promise, representation, or statement, written or otherwise, between
Executive and the Company with regard to this subject matter. This Agreement is
entered into without reliance on any promise, representation, statement or
agreement other than those expressly contained or incorporated herein, and it
cannot be modified or amended except in a writing signed by Executive and a duly
authorized officer of the Company.

          10.5  Counterparts. This Agreement may be executed in separate
counterparts, any one of which need not contain signatures of more than one
party, but all of which taken together will constitute one and the same
Agreement.

          10.6  Headings.  The headings of the sections hereof are inserted for
convenience only and shall not be deemed to constitute a part hereof nor to
affect the meaning thereof.

          10.7  Successors and Assigns. This Agreement is intended to bind and
inure to the benefit of and be enforceable by Executive, the Company and their
respective successors, assigns, heirs, executors and administrators, except that
Executive may not assign any of his duties hereunder and he may not assign any
of his rights hereunder without the written consent of the Company, which shall
not be withheld unreasonably.

                                       9.
<PAGE>

          10.8  Attorneys' Fees. If either party hereto brings any action to
enforce his or its rights hereunder, the prevailing party in any such action
shall be entitled to recover his or its reasonable attorneys' fees and costs
incurred in connection with such action.

          10.9  Arbitration. To provide a mechanism for rapid and economical
dispute resolution, Executive and the Company agree that any and all disputes,
claims, or causes of action, in law or equity, arising from or relating to this
Agreement (including the Release) or its enforcement, performance, breach, or
interpretation, will be resolved, to the fullest extent permitted by law, by
final, binding, and confidential arbitration held in Orange County, California
and conducted by Judicial Arbitration & Mediation Services/Endispute ("JAMS"),
under its then-existing Rules and Procedures. Nothing in this Section 10.9 or in
this Agreement is intended to prevent either Executive or the Company from
obtaining injunctive relief in court to prevent irreparable harm pending the
conclusion of any such arbitration.

          10.10 Remedies.  Executive's duties under Section 8 and the Employee
Proprietary Information and Inventions Agreement shall survive termination of
Executive's employment with the Company.  Executive acknowledges that a remedy
at law for any breach or threatened breach by Executive of the provisions of
these sections and the Employee Proprietary Information and Inventions Agreement
would be inadequate, and that such a breach would cause irreparable harm to the
Company; and Executive therefore agrees that the Company shall be entitled to
injunctive relief in case of any such breach or threatened breach.

          10.11 Governing Law. All questions concerning the construction,
validity and interpretation of this Agreement will be governed by the law of the
State of California as applied to contracts made and to be performed entirely
within California.

     In Witness Whereof, the parties have executed this Agreement effective as
of the Effective Date above written.

WATSON PHARMACEUTICALS, INC.

By:___________________________
   Name:
   Title:

EXECUTIVE:

______________________________
Name:

                                       10.
<PAGE>

                                   Exhibit A

                   COMPENSATION AND SEVERANCE TERMS SCHEDULE

1.   BASE SALARY

     For services to be rendered under this Agreement, Executive shall receive
an initial base salary at an annualized rate of $___________, payable in
accordance with the Company's standard payroll practices, and subject to
increases as set forth in the Agreement.

2.   BONUS

     Executive's annual bonus, if granted, shall be at a target level of ____%
of the Executive's then current base salary.

3.   STOCK OPTIONS

     As of the Effective Date, Executive has outstanding option(s) to purchase
the number of shares of Company common stock as indicated on Attachment A to
this Exhibit A.

4.   SEVERANCE BENEFITS

     4.1  Termination By Company without Cause. If the Company terminates
Executive's employment at any time without Cause, the Company shall provide to
Executive, within thirty (30) days after the Effective Date of the Release
attached hereto as Exhibit B (as "Effective Date" is defined in the Release), as
the only severance compensation and benefits all of the following:

          (a)   A lump sum severance payment, subject to standard withholdings
or deductions, in an amount equal to the sum of: (i) twenty-four (24) months of
Executive's then base salary; (ii) two times Executive's target bonus to be
earned for the year in which termination occurs or two times the bonus amount
paid to the Executive in the prior year, whichever is greater; and (iii)
Executive's prorated bonus (based on Executive's target bonus amount) for the
year in which the termination occurs.

          (b)   Continued group health insurance benefits (e.g., medical,
dental, vision, etc.) for Executive and Executive's eligible dependents for a
period of up to eighteen (18) months under COBRA, and if Executive is not
covered under the Company's group health insurance plan at the end of eighteen
(18) months, the Company shall use its best efforts to provide Executive and
Executive's eligible dependents with comparable health insurance coverage for an
additional period of up six (6) months, but the Company shall not be obligated
to pay more than one hundred fifty percent (150%) of the cost of COBRA coverage
for such comparable coverage; provided, however, that in any event the Company's
obligation to provide any health benefits pursuant to this sentence ends when
Executive becomes eligible for health insurance with a new

                                       1.
<PAGE>

employer (and Executive agrees to promptly notify the Company in writing of any
such event of eligibility).

          (c)   Outplacement services for one year with a nationally recognized
service selected by the Company.

     4.2  Executive's Resignation for Good Reason. If Executive terminates his
employment with the Company for Good Reason, the Company shall provide to
Executive, within thirty (30) days after the Effective Date of the Release
attached hereto as Exhibit B (as "Effective Date" is defined in the Release), as
the only severance compensation and benefits, the same severance compensation
and benefits provided in Section 4.1 hereof.

     4.3  Change of Control Termination. In the event of a Change of Control
Termination, the Company shall provide to Executive, within thirty (30) days
after the Effective Date of the Release attached hereto as Exhibit B (as
"Effective Date" is defined in the Release), as the only severance compensation
and benefits, (a) the same severance compensation and benefits provided in
Section 4.1 hereof and, (b) any unvested Options held by Executive shall have
their vesting accelerated in full so as to become one hundred percent (100%)
vested and immediately exercisable in full as of the date of such termination.

                                       2.
<PAGE>

                                   Exhibit B

                               RELEASE AGREEMENT

I understand that my position with Watson Pharmaceuticals, Inc. (the "Company")
terminated effective _______________ (the "Separation Date").  The Company has
agreed that if I choose to sign this Release, the Company will, within thirty
(30) days after the Effective Date of this Release,  pay me certain severance
benefits (minus the standard withholdings and deductions) pursuant to the terms
of the Key Employee Agreement (the "Agreement") entered into as of
______________, 1999, between myself and the Company, and any agreements
incorporated therein by reference.  I understand that I am not entitled to such
severance benefits unless I sign this Release.  I further understand that,
regardless of whether I sign this Release, the Company will pay me all of my
accrued salary and paid time off through the Separation Date, to which I am
entitled by law.

In consideration for the severance benefits I am receiving under the Agreement,
I hereby release the Company and its officers, directors, agents, attorneys,
employees, shareholders, parents, subsidiaries, and affiliates from any and all
claims, liabilities, demands, causes of action, attorneys' fees, damages, or
obligations of every kind and nature, whether they are now known or unknown,
arising at any time prior to the date I sign this Release.  This general release
includes, but is not limited to:  all federal and state statutory and common law
claims, claims related to my employment or the termination of my employment or
related to breach of contract, tort, wrongful termination, discrimination,
harassment, defamation, fraud, wages or benefits, or claims for any form of
equity or compensation.  Notwithstanding the release in the preceding sentence,
I am not releasing any right of indemnification I may have for any liabilities
and costs of defense (including without limitation reasonable attorneys' fees)
arising from my actions within the course and scope of my employment with the
Company.

In releasing claims unknown to me at present, I am waiving all rights and
benefits under Section 1542 of the California Civil Code, and any law or legal
principle of similar effect in any jurisdiction:  "A general release does not
extend to claims which the creditor does not know or suspect to exist in his
favor at the time of executing the release, which if known by him must have
materially affected his settlement with the debtor."

If I am forty (40) years of age or older as of the Separation Date, I
acknowledge that I am knowingly and voluntarily waiving and releasing any rights
I may have under the federal Age Discrimination in Employment Act of 1967, as
amended ("ADEA").  I also acknowledge that the consideration given for the
waiver in the above paragraph is in addition to anything of value to which I was
already entitled.  I have been advised by this writing, as required by the ADEA
that:  (a) my waiver and release do not apply to any claims that may arise after
my signing of this Release; (b) I should consult with an attorney prior to
executing this Release; (c) I have twenty-one (21) days (forty-five (45) days in
the event of a group termination) within which to consider this Release
(although I may choose to voluntarily execute this Release earlier); (d) I have
seven (7) days following the execution of this release to revoke the Release;
and (e) this Release will not be effective until the eighth day after this
Release has been signed both by me and by the Company ("Effective Date").

Agreed:

___________________________             ________________________________________
      Date                              [Employee]

___________________________             ________________________________________
      Date                              WATSON PHARMACEUTICALS, INC.
<PAGE>

                                   Exhibit C

           EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT<PAGE>

                                                                   Exhibit 10.12

[*] Confidential treatment requested

                            DISTRIBUTION AGREEMENT

DISTRIBUTION AGREEMENT dated this 24th day of June, 1993, by and between

R&D Laboratories, Inc. with offices at 4204 Glencoe Ave., Marina del Rey, CA
90292, United States of America

                                            - hereinafter referred to as "R&D" -

                                            and

Rhone-Poulenc Rorer GmbH, a German company with offices at Nattermannallee 1, D-
5000 Koln 30, Germany

                                            - hereinafter referred to as "RPR" -

                                  WITNESSETH
                                  ----------

WHEREAS, R&D and RPR have entered into discussions about the distribution of a
pharmaceutical product containing iron gluconate whereby RPR is willing to grant
to R&D a distribution right; and

WHEREAS, R&D wishes to obtain such distribution right on the terms and
conditions set forth herein.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and
obligations set forth herein, the parties hereto agree as follows:

ARTICLE 1 - Definitions
-----------------------

The following terms, as used in this Agreement, shall have the meanings set
forth in this Article:

1.1   "Affiliate" shall mean all corporations or business entities which,
      directly or indirectly, are controlled by, do control, or are under common
      control with R&D or RPR. For this purpose the meaning of the word
      "control" shall mean the ownership of fifty percent (50%) or more of the
      shares or voting rights of interest of such corporation or business
      entity.

1.2   "NDA" shall mean a New Drug Application, as defined in the Drug Laws of
      the States of the Territory and applicable regulations promulgated
      thereunder.
<PAGE>

1.3   "Agreement Period" shall mean the period commencing upon the date set
      forth above and extending until twelve (12) full calendar years from such
      date, with such Period being automatically renewable for successive two
      (2) year periods, unless either party shall notify the other of its desire
      to terminate this Agreement not less than one hundred and eighty (180)
      days before expiration of the Initial Period of this Agreement or the
      subsequent Period then in effect, as the case may be.

1.4   "Compounds" shall mean the iron gluconate product, its analogs,
      modifications and improvements, as well as any other related compounds
      which are owned or otherwise lawfully entitled to be used by RPR.

1.5   "Product" shall mean any speciality in every pharmaceutical form
      containing a Compound ready for application either alone or in combination
      with other active ingredients.

1.6   "RPR know-how" shall mean all technology, formulae, trade secrets,
      technical data, preclinical and clinical data, toxicological and
      pharmacological data and any other information or experience owned,
      controlled or possessed by RPR relating to or useful in connection with
      the Compounds and/or Product as well as any improvements or modifications
      to the Know-how developed by RPR, including, but not limited to, such data
      or information as will enable R&D to use efficiently the Compounds.

1.7   "R&D know-how" shall mean all technology, formulae, trade secrets,
      technical data, preclinical and clinical data, toxicological and
      pharmacological data and any other information or experience owned,
      controlled or possessed by R&D relating to or useful in connection with
      the Compounds and/or Product, as well as any improvements or modifications
      to the Know-how developed by R&D, including but not limited to, such data
      or information as will enable R&D to manufacture efficiently the Products.

1.8   "R&D Territory" shall mean the countries listed in Exhibit A.

1.9   "RPR Territory" shall mean the rest of the world excluding R&D territory.

1.10  "Joint Know-how" shall mean all Know-how which the parties to the
      Agreement have obtained together or in the costs of which they have
      participated.

ARTICLE 2 - Grant; Trademark
----------------------------

2.1   RPR hereby grants to R&D during the Agreement Period an exclusive license
      to import the Products from RPR and use and sell Products in the R&D
      Territory under the RPR know-how, with the right to subdistribute in whole
      or in part, to its affiliates or third parties. Any subdistributor will
      bear the same obligations as R&D insofar as possible in this Agreement.

2.2   RPR warrants with R&D that it is the sole and exclusive owner of the
      Compounds and has the sole and exclusive right, without any restrictions,
      to disclose information on the Compounds and to grant the distribution
      rights as set out herein and has not granted any other rights with respect
      to the Compounds in the Territory; that it knows of no other

                                       2
<PAGE>

      person or enterprise which is working with the Compounds within the
      Territory; that there is no action threatened or pending against any of
      the Compounds in the Territory; that it does not know of any problems
      concerning the safety or efficacy of the Compounds or of any questions
      raised by any regulatory body in any country in the Territory and that it
      has informed R&D of all adverse drug reactions known to it; that it does
      not need the consent or approval of any third party, court or governmental
      agency to enter into this Agreement; that it does not know of any patents
      or patent applications which upon issuing as patents would be infringed by
      the sale or supply of the Compounds within the Territory; that it does not
      know of any circumstances and has not done any acts which are inconsistent
      with the terms and purposes of this Agreement.

2.3   In the event R&D decides not to submit an NDA for any Product, this
      Agreement shall be terminated upon thirty (30) days' written notice by R&D
      to RPR, and R&D, upon request of RPR, shall furnish all R&D know-how
      regarding all Compounds/ Products to RPR.

      RPR, its affiliates and/or its licensees and distributors have the right
      to use such R&D know-how without limitation and costs.

2.4   If, during the Agreement Period, R&D shall make an improvement concerning
      Compound/Product (such as for example an improved process for the
      manufacture of Product) for which patent applications can be filed by R&D,
      R&D shall have the right to file such applications in R&D's name in the
      R&D Territory with the exclusive right thereto; joint applications in the
      name of R&D and of RPR shall be filed in countries outside the R&D
      Territory agreed upon.

2.5   RPR or one of its affiliates shall grant R&D a registered Trademark of
      RPR, and R&D shall use said Trademark for the Product under the Trademark
      Agreement to be negotiated separately. In the event there is no Trademark,
      RPR will file a new Trademark in the respective country after consulting
      R&D.

ARTICLE 3 - Evaluation
----------------------

R&D shall, at its own expense, perform all clinical trials required in
connection with a New Drug Approval, filing an IND accordingly. If requested by
the Health Authorities, R&D shall carry out as well any preclinical work in
addition to the data submitted by RPR.

RPR shall provide R&D free of charge with all clinical samples required for the
clinical trials.

ARTICLE 4 - Diligence
---------------------

R&D agrees that it shall use its best efforts, itself or through its
subdistributors, to obtain Board of Health registrations and other necessary
authorizations to market the Product in each country of the original Territory
as soon as possible after obtaining such authorizations.  If, in any country,
R&D shall fail to have introduced the Product within one year after obtaining
the last necessary governmental authorization, RPR shall have the right to
terminate this Agreement as to the country concerned upon six months written
notice to R&D of RPR's intent to do so, provided, however, that such termination
shall not take effect if R&D shall introduce the Product in that country before
the expiration of the six month's notice period.  This provision shall not

                                       3
<PAGE>

apply to any country in which R&D's failure to market the Product within the
time provided shall be for reasons beyond the control of R&D.

ARTICLE 5 - Delivery
---------------------

During the Agreement Period RPR shall supply R&D with, and R&D shall purchase
from, RPR or from sources indicated by RPR, all requirements of the Product at
the conditions established in Exhibit B.

ARTICLE 6 - Infringement and Indemnification
--------------------------------------------

6.1   If R&D is required by a final determination of a court of competent
      jurisdiction to obtain a license from any third party (other than RPR)
      under any patent not licensed hereunder in order to manufacture, use or
      sell the Product, and to pay a royalty under such license, and the
      infringement of such patent cannot reasonably be avoided by R&D, then R&D
      and RPR shall negotiate in good faith a solution for this situation.

6.2   If a third party obtains, by order, decree or grant from a competent
      governmental authority, a compulsory license authorizing such third party
      to manufacture, use or sell any Product sold by R&D, RPR shall give prompt
      notice to R&D. For the effective period of such compulsory license, R&D
      and RPR shall negotiate a solution for this situation.

6.3   In the event that the claims covering the Product contained in the Patent
      Rights are declared invalid or unenforceable by a judgement, decree or
      decision of a court, tribunal or other authority of competent
      jurisdiction, then R&D and RPR shall renegotiate the terms and conditions
      of this Agreement in good faith.

ARTICLE 7 - Responsibilities / Product liability
------------------------------------------------

7.1   R&D shall hold RPR harmless from any product liability claims or from any
      product liability damages arising from the R&D Territory in relation to
      R&D's or its Distributing Partners, mishandling of the Compound and to the
      use of the Product. It is agreed that R&D promptly notifies RPR of any
      such claims and that R&D cooperates with RPR in defending against such
      claims, and provided that also such claims or damages do not result in
      whole or in part from any negligence or defects attributable to RPR (as to
      which RPR indemnities R&D), and provided that RPR promptly notifies R&D of
      preclinical and clinical data relating to any serious or previously
      unknown side effects of or adverse reaction to this Product. RPR will not
      (except as provided in the parenthetical above) have to bear any damages
      or financial indemnity for R&D, its distributors or a third party.

7.2   RPR is not responsible in case the production site is not approved by the
      FDA.

ARTICLE 8 - Breach; Termination
-------------------------------

8.1   In the event of a breach or default of this Agreement by either party
      which is not remedied within ninety (90) days after the receipt of notice
      thereof from the other party,

                                       4
<PAGE>

      the party not in breach or default shall be entitled (without prejudice to
      any of its other rights) to terminate this Agreement by giving notice to
      take effect immediately. The right to terminate this Agreement, as
      hereinafter provided, shall not be affected in any way by a waiver of, or
      failure to, take action with respect to any previous default.

8.2   At R&D's sole option, this Agreement shall be deemed terminated
      immediately in the event that the Product is withdrawn from the market as
      a result of actual or threatened regulatory action by the U.S. Ministry of
      Health and Welfare or other governmental entity. R&D shall provide RPR
      with a written notice of such termination.

ARTICLE 9 - Exchange of Information; Confidentiality
----------------------------------------------------

9.1   RPR has provided R&D with all RPR know-how available. RPR shall also be
      under a continuing obligation to provide R&D promptly with all RPR know-
      how during the Agreement Period.

      R&D also shall be under a continuing obligation to provide RPR promptly
      with all R&D Know-how during the Agreement Period.

9.2   R&D and/or its subdistributors shall be allowed to use free of charge the
      RPR know-how in the R&D-Territory for their development and marketing
      efforts. RPR shall be allowed to use free of charge the R&D know-how and
      to have the R&D know-how used free of charge in its own territory for its
      development and marketing efforts.

9.3   R&D agrees that during the validity of this Agreement and for a period of
      five (5) years from the date of termination of this Agreement it shall:

      a)  not disclose RPR know-how provided pursuant to Article 9.1. and R&D
          know-how to third parties except to the U.S. Ministry of Health and
          Welfare and other governmental authorities, or Affiliates,
          subdistributors and consultants of R&D pursuant to a non-disclosure
          commitment; and

      b)  take such precautions with RPR know-how as it normally takes with its
          own confidential and proprietary information to prevent disclosure to
          third parties (except Affiliates and consultants as above).

9.4   RPR agrees that during the validity of the Agreement Period and for the
      period of five (5) years from the date of termination of this Agreement it
      shall:

      a)  not disclose R&D know-how pursuant to Article 9.1. to third parties
          except to any governmental authorities or licensees its territory.
          Affiliates and consultants of RPR, pursuant to a non-disclosure
          commitment; and

      b)  take such precautions with R&D know-how as it normally takes with its
          own confidential and proprietary information to prevent disclosure to
          third parties (except Affiliates and consultants as above).

                                       5
<PAGE>

9.5  The obligations of RPR and R&D under Articles 9.3. and 9.4. shall not, in
     any event, apply to any information which:

     a)   at the time of disclosure is or thereafter becomes available to the
          public in published literature or otherwise through no fault of either
          party; or

     b)   was known to, or otherwise in the possession of, either party or an
          Affiliate prior to the receipt of such information from the other
          party; or

     c)   is obtained by either party from a source other than one of the
          parties and other than one who would be breaching a commitment of
          confidentiality to one party by disclosing such information to the
          other party.

     d)   derive from clinical trials and are necessary and useful to fullfill
          marketing purposes provided the disclosure is not damaging the
          Product.

ARTICLE 10 - Meetings / Cooperation
-----------------------------------

R&D and RPR agree to meet during the Agreement Period at a mutually agreeable
time and place for the purpose of exchanging information regarding the Compound
and Product.

The joint Know-how can be used free of charge by either party in its territory.

ARTICLE 11 - Licence Reference
------------------------------

All packages distributed by R&D will bear the licence reference "Distributed in
 ... by R&D Laboratories, Inc., 4204 Glencoe Ave., Marina del Rey, CA 90292, USA
(800) 338-9066 in licence of Rhone-Poulenc Rorer."

Any notice or communication required or permitted to be given or made under this
Agreement by one of the parties hereto to the other shall be in writing and
shall be deemed to have been sufficiently given or made for all purposes if
mailed by registered mail, postage prepaid, addressed to such other party at its
respective address as follows:

                            R&D LABORATORIES, INC.
                            4204 Glencoe Ave.
                            Marina del Rey, CA 90292
                            U.S.A.

                            Attention: Executive Vice President

                            RHONE-POULENC RORER GMBH
                            Nattermannallee 1
                            D - 5000 Cologne 30
                            Germany

                            Attention: Geschaftsleitung

                                       6
<PAGE>

Service of any notice or communication shall be deemed to be complete three (3)
business days after mailing.

ARTICLE 12 - Force Majeure
--------------------------

Neither party shall be responsible or liable to the other hereunder for failure
or delay in performance of this Agreement due to any war, fire, accident or
other casualty, or any labor disturbance or Act of God or the public enemy, or
any other contingency beyond such party's reasonable control.  In addition, in
the event of the applicability of this Article, the party affected by such Force
Majeure shall use its best efforts to eliminate, cure and overcome any of such
causes and resume performance of its obligations.

ARTICLE 13 - Transfer of Health/Trademark Registration
------------------------------------------------------

After expiration of the Agreement R&D and/or its subdistributors will transfer
to RPR without any costs for RPR the health registration(s) and, in case a
Trademark owned by R&D and/or its subdistributors is used, the Trademark
registration to RPR or a company named by RPR.

ARTICLE 14 - Assignment
-----------------------

This Agreement and all rights and obligations hereunder are personal to the
parties hereto and may not be assigned, other than to Affiliates as defined
herein, without the express prior written consent of the other.  Any assignment
or attempt at same in the absence of such prior written consent shall be void
and without effect.

ARTICLE 15 - Governing Law
--------------------------

This Agreement shall be construed, and the rights of the parties determined, in
accordance with the Swiss law.

ARTICLE 16 - Severability
-------------------------

If any one or more of the provisions of this Agreement shall be held to be
invalid, illegal or unenforceable, the validity, legality or enforceability of
the remaining provisions hereof shall not in any way be affected or impaired
thereby.  In the event any provisions shall be held invalid, illegal or
unenforceable, the parties shall use best efforts to substitute a valid, legal
and enforceable provision, which insofar as practical, implements the purposes
hereof.

ARTICLE 17 - Entire Agreement
-----------------------------

This Agreement constitutes the entire understanding between the parties relating
to the subject matter hereof, and no amendment or modification to this Agreement
shall be valid or binding upon the parties unless made in writing and signed by
the representatives of such parties.

ARTICLE 18 - Arbitration
------------------------

All disputes, controversies, or differences which may arise between the parties
out of, or in relation to, or in connection with, this Agreement or for the
breach thereof, shall be finally

                                       7
<PAGE>

settled by arbitration underlying Swiss law by which either party hereto is
bound. The arbitration proceedings with the application of Swiss law shall take
place in Zurich, Switzerland.

ARTICLE 19 - Miscellaneous
--------------------------

In case any question arises between the parties hereto in connection with the
matter not provided for in this Agreement, the parties hereto shall confer
friendly with each other to reach a decision.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first written
above.

Cologne, June 24, 1993                       Marina del Rey

RHONE-POULENC RORER GMBH                     R&D LABORATORIES, INC.

                                       8
<PAGE>

                                   EXHIBIT A

                        FOR THE DISTRIBUTION AGREEMENT

between

R&D Laboratories, Inc., 4204 Glencoe Ave., Marina del Rey, 90292 CA,
United States of America

and

Rhone-Poulenc Rorer GmbH, Nattermannallee 1, D-5000 Koln 30,
Germany

                                 COUNTRY LIST
                                 ------------

                 United States of America and its possessions

                                      [*]

Cologne, July 6, 1993                        Marina del Rey, July 20, 1993

RHONE-POULENC RORER GMBH                     R&D LABORATORIES, INC.
<PAGE>

                                   EXHIBIT B

                        FOR THE DISTRIBUTION AGREEMENT

between

R&D Laboratories, Inc., 4204 Glencoe Ave., Marina del Rey, 90292 CA,
United States of America

and

Rhone-Poulenc Rorer GmbH, Nattermannallee 1, D-5000 Koln 30,
Germany

                              Delivery Conditions
                              -------------------

     -  ex factory

     -  minimum annual quantity
           [*] of each [*]

     It is understood and agreed that R & D Laboratories, Inc. shall not be
     required to purchase any quantity of any product in any country of the
     territory until receipt of Board of Health registrations and/or
     authorizations necessary to market the Product in the respective country.

     -  minimum quantity per purchase order
           [*] of each [*]

                                    Pricing
                                    -------

Ferrlecit ampoules   [*] x [*] ml         [*]
           ex factory

                                    Payment
                                    -------

Delivery against irrevocable and confirmed Letter of Credit at sight.

Cologne, July 6, 1993                        Marina del Rey, Aug. 2, 1993

RHONE-POULENC RORER GMBH                     R&D LABORATORIES, INC.
<PAGE>

                                  AMENDMENT 1

                        FOR THE DISTRIBUTION AGREEMENT

between

R&D Laboratories, Inc., 4204 Glencoe Ave., Marina del Rey, 90292 CA,
United States of America

and

Rhone-Poulenc Rorer GmbH, Nattermannallee 1, D-5000 Koln 30, Germany

                                DURATION PERIOD
                                ---------------

Modification of Article 1.3 - Agreement Period
----------------------------------------------

The Agreement Period is defined as duration of ten (10) full calendar years
after FDA market approval of the first product in the US-market.

All other stipulation of the Agreement of June 24, 1993 remain unchanged.

Cologne                                      Marina del Rey

Rhone-Poulenc Rorer GmbH                     R&D LABORATORIES, INC.
<PAGE>

                                  EXHIBIT A/1

between

R&D Laboratories, Inc., 4640 Admiralty Way, Ste. 710, Marina del Rey,
90292 CA, United States of America

and

Rhone-Poulenc Rorer GmbH, Nattermannallee 1, D-5000 Koln 30, Germany

                                 COUNTRY LIST
                                 ------------

Additional countries:

                                      [*]

Cologne                                      Marina del Rey,

RHONE-POULENC RORER GMBH                     R&D LABORATORIES, INC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]